Mother-to-fetus transfer of antiviral drugs and the involvement of transporters at the placental barrier

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3708-3718

  Tomi, Masatoshi ^a   Nishimura, Tomohiro ^a   Nakashima, Emi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Drug transport; Multidrug resistance transporters; Nucleoside transporters; Organic anion transporters; Placenta; Pregnancy

Indexed keywords

ABACAVIR; ABC TRANSPORTER; ACICLOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; CARRIER PROTEIN; CONNEXIN 26; DARUNAVIR; DIDANOSINE; GANCICLOVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN; NELFINAVIR; NUCLEOSIDE TRANSPORTER; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC CATION TRANSPORTER; OSELTAMIVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; VALACICLOVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL THERAPY; BLOOD BRAIN BARRIER; CHORION VILLUS; CONGENITAL MALFORMATION; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG UPTAKE; FETUS BLOOD; FETUS DISEASE; GENETIC POLYMORPHISM; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA A; INFLUENZA B; MATERNAL BLOOD; NONHUMAN; PLACENTA; PLACENTAL TRANSFER; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; STILLBIRTH; SYNCYTIOTROPHOBLAST; VERTICAL TRANSMISSION;

EID: 79960116789     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22642     Document Type: Review

References (101)

1. Mak TK, Mangtani P, Leese J, Watson JM, Pfeifer D. 2008. Influenza vaccination in pregnancy: Current evidence and selected national policies. Lancet Infect Dis 8:44-52.
2. Mofenson LM. 2010. Prevention in neglected subpopulations: Prevention of mother-to-child transmission of HIV infection. Clin Infect Dis 50(Suppl 3):S130-S148.
3. Gude NM, Roberts CT, Kalionis B, King RG. 2004. Growth and function of the normal human placenta. Thromb Res 114:397-407.
4. Gedeon C, Koren G. 2006. Designing pregnancy centered medications: Drugs which do not cross the human placenta. Placenta 27:861-868.
5. Vahakangas K, Myllynen P. 2009. Drug transporters in the human blood-placental barrier. Br J Pharmacol 158:665-678.
6. Kitano T, Iizasa H, Hwang IW, Hirose Y, Morita T, Maeda T, Nakashima E. 2004. Conditionally immortalized syncytiotrophoblast cell lines as new tools for study of the blood-placenta barrier. Biol Pharm Bull 27:753-759.
7. Shin BC, Suzuki T, Matsuzaki T, Tanaka S, Kuraoka A, Shibata Y, Takata K. 1996. Immunolocalization of GLUT1 and connexin 26 in the rat placenta. Cell Tissue Res 285:83-89.
8. Gabriel HD, Jung D, Butzler C, Temme A, Traub O, Winterhager E, Willecke K. 1998. Transplacental uptake of glucose is decreased in embryonic lethal connexin26-deficient mice. J Cell Biol 140:1453-1461.
9. Kingdom J, Huppertz B, Seaward G, Kaufmann P. 2000. Development of the placental villous tree and its consequences for fetal growth. Eur J Obstet Gynecol Reprod Biol 92:35-43.
10. Gauster M, Huppertz B. 2008. Fusion of cytothrophoblast with syncytiotrophoblast in the human placenta: Factors involved in syncytialization. J Reprod Med Endocrinol 5:76-82.
11. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. 1997. Regulation of human placental development by oxygen tension. Science 277:1669-1672.
12. Demir R, Kaufmann P, Castellucci M, Erbengi T, Kotowski A. 1989. Fetal vasculogenesis and angiogenesis in human placental villi. Acta Anat (Basel) 136:190-203.
13. Jaffe R, Jauniaux E, Hustin J. 1997. Maternal circulation in the first-trimester human placenta-Myth or reality? Am J Obstet Gynecol 176:695-705.
14. Luckhardt M, Leiser R, Kingdom J, Malek A, Sager R, Kaisig C, Schneider H. 1996. Effect of physiologic perfusion-fixation on the morphometrically evaluated dimensions of the term placental cotyledon. J Soc Gynecol Investig 3:166-171.
15. Khong TY, De Wolf F, Robertson WB, Brosens I. 1986. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 93:1049-1059.
16. MacFarland A, Abramovich DR, Ewen SW, Pearson CK. 1994. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem J 26:417-423.
17. Hutson JR, Koren G, Matthews SG. 2010. Placental P-glycoprotein and breast cancer resistance protein: Influence of polymorphisms on fetal drug exposure and physiology. Placenta 31:351-357.
18. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK. 2005. Variable expression of MRP2 (ABCC2) in human placenta: Influence of gestational age and cellular differentiation. Drug Metab Dispos 33:896-904.
19. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, Meier PJ, Marin JJ. 2000. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 279:R1495-R1503.
20. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
21. Leslie EM, Deeley RG, Cole SP. 2005. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237.
22. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. 2006. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27:602-609.
23. Wang H, Wu X, Hudkins K, Mikheev A, Zhang H, Gupta A, Unadkat JD, Mao Q. 2006. Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: Effects of pregnancy and correlations with nuclear receptors. Am J Physiol Endocrinol Metab 291:E1295-E1304.
24. Gil S, Saura R, Forestier F, Farinotti R. 2005. P-Glycoprotein expression of the human placenta during pregnancy. Placenta 26:268-270.
25. Mathias AA, Hitti J, Unadkat JD. 2005. P-Glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 289:R963-R969.
26. Morimoto K, Nakakariya M, Shirasaka Y, Kakinuma C, Fujita T, Tamai I, Ogihara T. 2008. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos 36:6-9.
27. Ose A, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Fujita T, Yamamoto A, Sugiyama Y. 2008. P-Glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos 36:427-434.
28. Van Der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, Breimer DD. 2001. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 15:483-491.
29. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, Back DJ. 2001. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance? AIDS 15:1353-1358.
30. Agarwal S, Pal D, Mitra AK. 2007. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 339:139-147.
31. Zastre JA, Chan GN, Ronaldson PT, Ramaswamy M, Couraud PO, Romero IA, Weksler B, Bendayan M, Bendayan R. 2009. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 87:1023-1036.
32. Shaik N, Giri N, Pan G, Elmquist WF. 2007. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 35:2076-2085.
33. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, Hidalgo IJ, Rhodes GR, Ray AS. 2007. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 51:3498-3504.
34. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H. 2009. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull 32:1588-1593.
35. Nagashige M, Ushigome F, Koyabu N, Hirata K, Kawabuchi M, Hirakawa T, Satoh S, Tsukimori K, Nakano H, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. 2003. Basal membrane localization of MRP1 in human placental trophoblast. Placenta 24:951-958.
36. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. 2002. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2295-2301.
37. Meyer Zu Schwabedissen HE, Grube M, Heydrich B, Linnemann K, Fusch C, Kroemer HK, Jedlitschky G. 2005. Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: Effects of gestational age and cellular differentiation. Am J Pathol 166:39-48.
38. Karla PK, Quinn TL, Herndon BL, Thomas P, Pal D, Mitra A. 2009. Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux. J Ocul Pharmacol Ther 25:121-132.
39. Pan G, Giri N, Elmquist WF. 2007. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos 35:1165-1173.
40. Kim HS, Sunwoo YE, Ryu JY, Kang HJ, Jung HE, Song IS, Kim EY, Shim JC, Shon JH, Shin JG. 2007. The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol 64:645-654.
41. Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse CM, Hayashi J, Unadkat JD. 2007. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol 293:R1809-R1822.
42. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD. 2001. Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol 18:161-167.
43. Ugele B, St-Pierre MV, Pihusch M, Bahn A, Hantschmann P. 2003. Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab 284:E390-E398.
44. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H. 2002. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 300:918-924.
45. Sata R, Ohtani H, Tsujimoto M, Murakami H, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Nagata H, Tsukimori K, Nakano H, Sawada Y. 2005. Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther 315:888-895.
46. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H, Martinez-Picado J. 2009. Transport of lamivudine [(-)-beta-L-2', 3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 329:252-261.
47. Petropoulos S, Kalabis GM, Gibb W, Matthews SG. 2007. Functional changes of mouse placental multidrug resistance phosphoglycoprotein (ABCB1) with advancing gestation and regulation by progesterone. Reprod Sci 14:321-328.
48. Verhaagh S, Schweifer N, Barlow DP, Zwart R. 1999. Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics 55:209-218.
49. St-Pierre MV, Hagenbuch B, Ugele B, Meier PJ, Stallmach T. 2002. Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab 87:1856-1863.
50. Rizwan AN, Burckhardt G. 2007. Organic anion transporters of the SLC22 family: Biopharmaceutical, physiological, and pathological roles. Pharm Res 24:450-470.
51. Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP. 2001. Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol 21:4188-4196.
52. Lee WK, Wolff NA, Thevenod F. 2009. Organic cation transporters: Physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab 10:617-631.
53. Desforges M, Sibley CP. 2010. Placental nutrient supply and fetal growth. Int J Dev Biol 54:377-390.
54. Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, Louie J, Doyle TJ, Crockett M, Lynfield R, Moore Z, Wiedeman C, Anand M, Tabony L, Nielsen CF, Waller K, Page S, Thompson JM, Avery C, Springs CB, Jones T, Williams JL, Newsome K, Finelli L, Jamieson DJ, Pandemic H1N1 Influenza in Pregnancy Working Group. 2010. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 303:1517-1525.
55. Irving WL, James DK, Stephenson T, Laing P, Jameson C, Oxford JS, Chakraverty P, Brown DW, Boon AC, Zambon MC. 2000. Influenza virus infection in the second and third trimesters of pregnancy: A clinical and seroepidemiological study. BJOG 107:1282-1289.
56. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. 2009. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 181:55-58.
57. Greer LG, Sheffield JS, Rogers VL, Roberts SW, McIntire DD, Wendel GD Jr. 2010. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. Obstet Gynecol 115:711-716.
58. Worley KC, Roberts SW, Bawdon RE. 2008. The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Infect Dis Obstet Gynecol 2008:927574.
59. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. 1999. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104:1441-1447.
60. Rahi M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C, Laine K. 2008. Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta. Hum Exp Toxicol 27:65-71.
61. Hitzl M, Schaeffeler E, Hocher B, Slowinski T, Halle H, Eichelbaum M, Kaufmann P, Fritz P, Fromm MF, Schwab M. 2004. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 14:309-318.
62. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S. 2001. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137.
63. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, Sugiyama Y. 2009. Limited brain distribution of [3R, 4R, 5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 37:315-321.
64. Pacifici GM. 2005. Transfer of antivirals across the human placenta. Early Hum Dev 81:647-654.
65. Foster C, Lyall H. 2008. HIV and mitochondrial toxicity in children. J Antimicrob Chemother 61:8-12.
66. Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, Firtion G, Pons G, Mandelbrot L. 2004. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 48:4332-4336.
67. Pons JC, Taburet AM, Singlas E, Delfraissy JF, Papiernik E. 1991. Placental passage of azathiothymidine (AZT) during the second trimester of pregnancy: Study by direct fetal blood sampling under ultrasound. Eur J Obstet Gynecol Reprod Biol 40:229-231.
68. Gillet JY, Garraffo R, Abrar D, Bongain A, Lapalus P, Dellamonica P. 1989. Fetoplacental passage of zidovudine. Lancet 2:269-270.
69. O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, Balsley J, Bryson YJ. 1993. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 168:1510-1516.
70. Schenker S, Johnson RF, King TS, Schenken RS, Henderson GI. 1990. Azidothymidine (zidovudine) transport by the human placenta. Am J Med Sci 299:16-20.
71. Liebes L, Mendoza S, Wilson D, Dancis J. 1990. Transfer of zidovudine (AZT) by human placenta. J Infect Dis 161:203-207.
72. Coan PM, Angiolini E, Sandovici I, Burton GJ, Constancia M, Fowden AL. 2008. Adaptations in placental nutrient transfer capacity to meet fetal growth demands depend on placental size in mice. J Physiol 586:4567-4576.
73. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larrayoz I, Martinez-Picado J, Casado FJ. 2005. Cell entry and export of nucleoside analogues. Virus Res 107:151-164.
74. Sai Y, Nishimura T, Shimpo S, Chishu T, Sato K, Kose N, Terasaki T, Mukai C, Kitagaki S, Miyakoshi N, Kang YS, Nakashima E. 2008. Characterization of the mechanism of zidovudine uptake by rat conditionally immortalized syncytiotrophoblast cell line TR-TBT. Pharm Res 25:1647-1653.
75. Nishimura T, Seki Y, Sato K, Chishu T, Kose N, Terasaki T, Kang YS, Sai Y, Nakashima E. 2008. Enhancement of zidovudine uptake by dehydroepiandrosterone sulfate in rat syncytiotrophoblast cell line TR-TBT 18d-1. Drug Metab Dispos 36:2080-2085.
76. Mandelbrot L, Peytavin G, Firtion G, Farinotti R. 2001. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol 184:153-158.
77. Pons JC, Boubon MC, Taburet AM, Singlas E, Chambrin V, Frydman R, Papiernik E, Delfraissy JF. 1991. Fetoplacental passage of 2', 3'-dideoxyinosine. Lancet 337:732.
78. Sandberg JA, Slikker W Jr. 1995. Developmental pharmacology and toxicology of anti-HIV therapeutic agents: Dideoxynucleosides. FASEB J 9:1157-1163.
79. Sato K, Sai Y, Nishimura T, Chishu T, Shimpo S, Kose N, Nakashima E. 2009. Influx mechanism of 2', 3'-dideoxyinosine and uridine at the blood-placenta barrier. Placenta 30:263-269.
80. Chishu T, Sai Y, Nishimura T, Sato K, Kose N, Nakashima E. 2008. Potential of various drugs to inhibit nucleoside uptake in rat syncytiotrophoblast cell line, TR-TBT 18d-1. Placenta 29:461-467.
81. Owen RP, Lagpacan LL, Taylor TR, De La Cruz M, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Giacomini KM. 2006. Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug Metab Dispos 34:12-15.
82. Chappuy H, Treluyer JM, Rey E, Dimet J, Fouche M, Firtion G, Pons G, Mandelbrot L. 2004. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 191:558-562.
83. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T, Swiss Mother + Child HIV Cohort Study. 2002. Transplacental passage of protease inhibitors at delivery. AIDS 16:889-893.
84. Molsa M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C, Laine K. 2005. Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther 78:123-131.
85. Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. 2008. Inhibition of placental P-glycoprotein: Impact on indinavir transfer to the foetus. Br J Clin Pharmacol 65:667-673.
86. Anzivino E, Fioriti D, Mischitelli M, Bellizzi A, Barucca V, Chiarini F, Pietropaolo V. 2009. Herpes simplex virus infection in pregnancy and in neonate: Status of art of epidemiology, diagnosis, therapy and prevention. Virol J 6:40.
87. Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, Alexander ER, Andrews EB. 2004. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 70:201-207.
88. +- and Cl(-) -coupled amino acid transporter ATB0, + and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther 308:1138-1147.
89. +) and Cl(-)-dependent neutral and cationic amino acid transporter B(0+). J Biol Chem 274:23740-23745.
90. +-dependent transport of basic, zwitterionic, and bicyclic amino acids by a broad-scope system in mouse blastocysts. J Biol Chem 260:12118-12123.
91. Van Winkle LJ, Tesch JK, Shah A, Campione AL. 2006. System B0, + amino acid transport regulates the penetration stage of blastocyst implantation with possible long-term developmental consequences through adulthood. Hum Reprod Update 12:145-157.
92. Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ. 1998. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 250:246-251.
93. Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH. 1998. Valacyclovir: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 246:470-475.
94. Leazer TM, Klaassen CD. 2003. The presence of xenobiotic transporters in rat placenta. Drug Metab Dispos 31:153-167.
95. Landsberger EJ, Hager WD, Grossman JH. 1986. Successful management of varicella pneumonia complicating pregnancy. A report of three cases. J Reprod Med 31:311-314.
96. Henderson GI, Hu ZQ, Johnson RF, Perez AB, Yang Y, Schenker S. 1992. Acyclovir transport by the human placenta. J Lab Clin Med 120:885-892.
97. Nyholm JL, Schleiss MR. 2010. Prevention of maternal cytomegalovirus infection: Current status and future prospects. Int J Womens Health 2:23-35.
98. Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Kiell JM, Soong SJ, Whitley RJ, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. 2003. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. J Pediatr 143:16-25.
99. Faulds D, Heel RC. 1990. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39:597-638.
100. Brandy RC, Schleiss MR, Witte DP, Siddiqi TA, Fame PT. 2002. Placental transfer of ganciclovir in a woman with acquired immunodeficiency syndrome and cytomegalovirus disease. Pediatr Infect Dis J 21:796-797.
101. Umapathy NS, Ganapathy V, Ganapathy ME. 2004. Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0, +). Pharm Res 21:1303-1310.